Physician profile
David E Lipson
NPI 1417946575
$6,002.92
in general payments reported to CMS, 2019-2025
25 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what 77% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $295 · 2021: $698 · 2022: $964 · 2023: $1,526 · 2024: $1,111 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,916.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $941.89 | 2020-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $940.99 | 2019-2025 | Absorica Ld, Winlevi, Blu-U |
| Ucb, INC. | $801.16 | 2019-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $734.32 | 2019-2025 | Jublia, Arazlo, Siliq |
| Lilly USA, LLC | $733.08 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $520.84 | 2021-2025 | Opzelura |
| Amgen INC. | $327.93 | 2021-2025 | Otezla, Otezla |
| Journey Medical Corporation | $167.05 | 2022-2025 | |
| Epi Health, LLC | $156.06 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $144.29 | 2020-2023 | |
| Genzyme Corporation | $139.98 | 2021-2025 | |
| Fidia Pharma USA INC. | $70.47 | 2024-2025 | |
| Galderma Laboratories, L.P. | $68.46 | 2024-2025 | Nemluvio |
| Helsinn Therapeutics (U.S.), INC. | $52.20 | 2019-2022 | |
| Leo Pharma INC. | $33.62 | 2023-2025 | Anzupgo, Adbry |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $31.59 | 2020-2024 | Poteligeo |
| Regeneron Healthcare Solutions, INC. | $19.23 | 2025 | Libtayo |
| Botanix Sb INC | $18.82 | 2025 | Sofdra |
| Blueprint Medicines Corporation | $16.13 | 2023 | |
| Biofrontera INC. | $15.43 | 2021 | |
| Fresenius Kabi USA, LLC | $15.00 | 2023 | |
| Dermira, INC. | $14.23 | 2020 | |
| Verrica Pharmaceuticals INC. | $13.95 | 2023 | Ycanth |
| Mission Pharmacal Company | $13.70 | 2021 | |
| Nabriva Therapeutics, Plc | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lipson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.